Orris

Ulcerative colitis treatment according to current guidelines

Reading File
Reading File
Finding Sources
Searching PubMed

"ulcerative colitis"[MeSH Terms] AND "guideline"[pt]

Searching the Web

ulcerative colitis treatment guidelines 2024 ACG AGA ECCO

Reading Article

PMID: 40701556

Reading File
Reading Web Page

https://gi.org/journals-publications/ebgi/alkazzi_aug2025

Ulcerative Colitis Treatment (Current Guidelines)

Treatment is guided primarily by two 2024-2025 updates: the ACG Clinical Guideline Update on Ulcerative Colitis in Adults (2025), the AGA Living Clinical Practice Guideline on Moderate-to-Severe UC (Gastroenterology, 2024), and the ECCO Guidelines on Therapeutics (Oct 2024). All use GRADE methodology. Choice of therapy depends on disease extent (proctitis vs. left-sided vs. extensive) and severity/complication risk (mild-moderate low-risk vs. moderate-severe high-risk).

1. Mild-to-moderate disease

Ulcerative proctitis
  • Rectal 5-ASA (mesalamine suppository, ≥1 g/day) is preferred over rectal steroids or oral therapy for induction (strong recommendation) - topical agents outperform oral mesalamine for isolated rectal disease - Yamada's Textbook of Gastroenterology, 7th ed, p. 1341.
  • Non-responders: add/switch to a topical corticosteroid (foam/suppository) or tacrolimus/beclomethasone suppository.
  • Maintenance: rectal 5-ASA 1 g/day.
Left-sided or extensive mild-to-moderate UC
  • Oral 5-ASA ≥ 2 g/day (or higher, up to 4.8 g/day) is first-line for induction; combining oral + rectal 5-ASA improves response versus oral alone.
  • Budesonide MMX (oral, gut-targeted steroid) is recommended for induction in patients not responding adequately to 5-ASA, with a strong recommendation, since it avoids systemic steroid exposure.
  • Maintenance: oral 5-ASA at ≥1.5 g/day continued long-term; systemic and topical corticosteroids and budesonide MMX are not used for maintenance (no steroid-sparing benefit, strong recommendation against).

2. Moderate-to-severe disease

Induction options (ACG/AGA 2024-2025), generally favoring biologics/small molecules over no treatment, with growing evidence to position advanced therapies earlier rather than "step therapy" through steroids alone:
  • Anti-TNF agents: infliximab, adalimumab, golimumab
  • Anti-integrin: vedolizumab
  • IL-12/23 or IL-23 antagonists: ustekinumab, guselkumab, risankizumab, mirikizumab
  • JAK inhibitors: tofacitinib, upadacitinib (upadacitinib specifically recommended for induction with a strong recommendation given rapid onset and high efficacy)
  • S1P receptor modulators: ozanimod, etrasimod
  • Oral budesonide MMX may still be used for moderately active disease.
Maintenance after successful induction: continue the same agent that induced remission (guselkumab, mirikizumab, risankizumab, vedolizumab, anti-TNF IV/SC, tofacitinib, or upadacitinib) rather than switching - all carry strong recommendations for continuation over discontinuation.
Positioning considerations: risk stratification (extensive disease, deep ulcers, prior hospitalization/corticosteroid use, young age at diagnosis, elevated CRP/calprotectin) favors earlier use of higher-efficacy biologics/small molecules rather than sequential step-up therapy - a Yamada's Gastroenterology treatment algorithm, p. 1341-1348.

3. Acute severe ulcerative colitis (hospitalized)

This is a medical emergency:
  • IV corticosteroids (e.g., methylprednisolone 40-60 mg/day) are first-line.
  • Day 3 reassessment (e.g., Oxford/Travis criteria or CRP + stool frequency) identifies steroid non-responders.
  • Rescue therapy for steroid-refractory disease: infliximab or cyclosporine (calcineurin inhibitor), with comparable efficacy; choice depends on prior biologic exposure and institutional experience.
  • Colectomy is indicated for those failing medical rescue therapy, or emergently for toxic megacolon, perforation, or uncontrolled hemorrhage.
  • VTE prophylaxis is recommended in all hospitalized UC patients regardless of rectal bleeding, given elevated thrombosis risk.

4. Surgery

Total proctocolectomy with ileal pouch-anal anastomosis (IPAA) is curative and indicated for medically refractory disease, dysplasia/cancer, or fulminant colitis unresponsive to rescue therapy.

5. Adjunctive/monitoring measures

  • Treat-to-target: clinical remission plus endoscopic (and increasingly histologic) healing rather than symptom control alone.
  • Fecal calprotectin and CRP for non-invasive monitoring.
  • Colorectal cancer surveillance colonoscopy beginning 8 years after diagnosis of extensive colitis, with a shorter interval individualized to risk factors.
  • Vaccination review and infection screening (hepatitis B, TB, varicella) before starting biologics/JAK inhibitors, per ECCO infection-prevention guidance.

Note on evolving evidence

The field is moving quickly. The ACG 2025 update and AGA 2024 living guideline (updated as new trial data emerge) both now favor earlier positioning of biologics/JAK inhibitors in moderate-severe disease over traditional step-therapy, and newer agents (guselkumab, mirikizumab, risankizumab, etrasimod) have only recently been incorporated. If you want, I can go deeper into any one area (e.g., choosing between biologics, acute severe UC management, or pediatric guidance) - the ESPGHAN/ECCO pediatric UC guideline was also just updated in 2025.
This is a shared conversation. Sign in to Orris to start your own chat.